A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.
Thomas YauPaul N M ChengJoanne ChiuGerry Gin Wai KwokRoland LeungAngela M LiuTan To CheungChi Tao NgPublished in: Investigational new drugs (2021)
The PACOX regimen demonstrated good anti-cancer activity and survival advantage in advanced pre-treated HCC with favourable safety profile. It warrants further phase II/III studies.
Keyphrases
- phase ii
- open label
- end stage renal disease
- clinical trial
- newly diagnosed
- ejection fraction
- locally advanced
- chronic kidney disease
- phase iii
- phase ii study
- prognostic factors
- peritoneal dialysis
- placebo controlled
- randomized controlled trial
- double blind
- nitric oxide
- rectal cancer
- free survival
- nitric oxide synthase
- study protocol